KDR and neoplasm: Anlotinib occupied the ATP-binding pocket of VEGFR2 tyrosine kinase and showed high selectivity and inhibitory potency (IC50 <1 nmol/L Therefore, it is believed that anlotinib combined with SLC might suppress tumor cell activity.